November 12, 2026
Low-grade serous ovarian cancer (LGSOC) is a rare sub-type that disproportionately impacts younger women. LGSOC is often diagnosed late, has a high recurrence rate and doesn’t respond well to treatment options currently available like chemotherapy. But Dr Dane Cheasley is determined to change that – and thanks to you, his team are working together every day to power breakthroughs.
Low-grade serous ovarian cancer isn’t really one disease. It’s actually three diseases hiding within one cancer, that all respond to different therapies. There is a real and urgent need to work out what the best therapies are for these women, which is exactly what the funding from OCRF is helping us do.
Dr Dane Cheasley, Lead researcher at The Peter MacCallum Cancer Centre.
Dr Cheasley and his team are testing new drug combinations thathave shown promise in treating other cancers but have never beenused on low grade serous ovarian cancer.

His research is focused on drugs already approved by theTherapeutic Goods Administration (TGA), to try get the besttreatments to clinical trial sooner.

To do that, Dr Cheasley is working with like-minded researchersaround the world, who are experts in growing ovarian cancertumours in a 3D model, so they can better dissect the innerworkings of the cancer and monitor how it responds to each drug.

Dr Cheasley knows the road to develop new drug treatments is long, but he also understands that working together is the most effective way to power breakthroughs.

If he can identify the most effective and least toxic drugcombinations, that show promise across all subtypes of LGSOC,Dr Cheasley could inform a new treatment to give women themodern, targeted options they deserve.
Your gift today has the power to change the future for women with ovarian cancer.
Please give generously.